Medicine and Dentistry
Adiponectin
6%
Age
12%
Assessment
5%
Association
6%
Behcet Disease
5%
Biological Marker
5%
BRCA1
8%
Breast
9%
Breast Cancer
100%
Cancer
7%
Cancer Growth
5%
Cancer Risk
6%
Chemotherapy
7%
Cohort Analysis
5%
Combination Therapy
19%
COVID-19
6%
Development
6%
Diagnosis
7%
Diseases
22%
Elacestrant
5%
Epidermal Growth Factor Receptor 2
5%
Eribulin
6%
Estrogen Receptor
13%
Gamma Urogastrone
5%
Gene
13%
Hazard Ratio
5%
Hispanic
5%
Homologous Recombination
7%
Hormone Receptor
8%
Hormone Therapy
23%
Inpatient
17%
Malignant Neoplasm
23%
Metastatic Breast Cancer
11%
Neoplasm
22%
Ovarian Cancer
5%
Overall Survival
7%
Patient
72%
Progression Free Survival
5%
Receptor
5%
Recurrent Disease
14%
Serum
5%
Single Nucleotide Polymorphism
7%
Survival
5%
Tamoxifen
7%
Therapeutic Procedure
33%
Toxicity
5%
Transforming Growth Factor
6%
Trastuzumab
6%
Triple Negative Breast Cancer
12%
Woman
21%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
5%
Breast Cancer
54%
Cancer Risk
8%
Capecitabine
8%
Chemotherapy
11%
Clinical Trial
10%
Diseases
12%
Elacestrant
5%
Gamma Urogastrone
5%
Hormone Receptor
5%
Lapatinib
6%
Leptin
7%
Malignant Neoplasm
15%
Metastatic Breast Cancer
13%
Neoplasm
16%
Overall Survival
5%
Paclitaxel
8%
Progression Free Survival
5%
Receptor
5%
Recurrent Disease
9%
Solid Malignant Neoplasm
5%
Sorafenib
5%
Tamoxifen
5%
Toxicity
7%
Trastuzumab
9%
Triple Negative Breast Cancer
5%
Biochemistry, Genetics and Molecular Biology
Adiponectin
13%
Age
7%
Allele
6%
Association
16%
Body Mass
5%
BRCA1
8%
Cancer Cell
5%
Case-Control Study
5%
Development
8%
Growth
6%
Homologous Recombination
5%
Mutation
11%
Nested Gene
19%
Single-Nucleotide Polymorphism
10%
Transforming Growth Factor
9%
Weight
5%
